Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

s regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

GlaxoSmithKline Forward-Looking Statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

Stock Exchange Release no. 27/2007

CONTACT: Contact: Helle Husted, Sr. Director, Investor Relations, T:+45-33-44-77-30, E: hth@genmab.com

Ticker Symbol: (:GNMSF)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/9/2008)...OK, Thailand, May 9 /PRNewswire-USNewswire/ -- An ...or the Protection of Animals (WSPA),is on stand-by...truck,Myanmar to assess and then relieve the suffe...depend on for food and their livelihoods., WSPA...culture,Organization of the United Nations (FAO) w...
(Date:5/9/2008)..., Fla., May 9 /PRNewswire-USNewswire/ -- Many stro...fects. These can include nausea and,vomiting with ...nic use.,Such symptoms can lead patients to discon...o pain management for physicians. The novel invest...g oral analgesic, provided pain,relief for patient...
(Date:5/9/2008)...LE, May 9 /PRNewswire-USNewswire/ -- The risk of t...prostatic hyperplasia (BPH), can be,reduced by cha...aining a,normal weight and eating a healthy diet. ...r Prevention Program at Fred Hutchinson Cancer Res...s that suggest men need not,feel helpless against ...
(Date:5/9/2008)... Cytopia,s development of early pipeline cancer dr...swire-FirstCall/ -- Cytopia Limited,(ASX: CYT) tod...er drug,discovery and development collaboration wi... leverages Cytopia,s early stage drug discovery pi...herapeutics that is one of the,fastest growing seg...
Breaking Medicine Technology:Animals That Cyclone Survivors Depend on Need Help Now 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 1Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 2Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 3Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 4Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 5Cell Genesys Reports Fourth Quarter and Year End 2007 Results 13069 6Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 1Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 2Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 3Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 4Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 5Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 6Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 7Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 8Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 9Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 10Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 11Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 12Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 13Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 14Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 15Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 16Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results 13067 17Dr Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness 13065 1Dr Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness 13065 2Closer Analysis Shows Consumer Groups Make Gains in Stem Cell Patent Challenges Against WARF 3B Appeal Still Planned Against Narrowed Claims 13063 1Closer Analysis Shows Consumer Groups Make Gains in Stem Cell Patent Challenges Against WARF 3B Appeal Still Planned Against Narrowed Claims 13063 2
...ents treated with VELCADE, cyclophosphamide,and p...8, 2007 /PRNewswire-FirstCall/ -- Millennium,Pharm...n of results,from clinical trials of VELCADE based...omplete response(1) (CR) rates in previously,treat...were,presented at the prestigious 11th Internation...
...gis Decreases Incidence of Recurrent Wheeze by,Alm... June 29, 2007,/PRNewswire-FirstCall/ -- Abbott an..., published in the July issue of Journal of,Pediat...vizumab),may reduce recurrent wheezing in prematur...y showed that premature infants without,chronic lu...
Other Medicine Technology:Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5
(Date:5/12/2008)...ON, May 13 /PRNewswire/ -- Chiltern, a leading glo...pened a new office in Lisbon,Portugal. Mr. Ricard...Manager. Mr. Diaz has over 10 years experience in ...harmacology, a Master,s in Clinical trials and,an ... clinical research,professionals, supporting Chilt...
(Date:5/12/2008)...itish researchers who pioneered treatments which h...ritis and other autoimmune diseases have been awar...r Biomedical Research, announced today. , Emerit... Feldmann, who have been carrying out research tog...were selected for the $100K award by an internatio...
(Date:5/12/2008)...ct proceeds despite non-compliance with California...t (CEQA)., LOS ANGELES, May 12 /PRNewswire-USNews...MC) today went ahead with the planned expansion of...urt Judge Thomas I. McKnew,Jr. has upheld charges...d.,The groundbreaking ceremony held today appears ...
(Date:5/12/2008)... First approved dental anesthetic reversal ag...armaceuticals, Inc., a,dental specialty pharmaceut...es Food and Drug Administration (FDA) has granted ...mesylate). OraVerse is the first,pharmaceutical ag...thesia,and the associated functional deficits resu...
Breaking Medicine News(10 mins):Health News:Chiltern Announces New Expansion in Portugal 2Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 2Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 3Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 4Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Novalar Receives FDA Approval for OraVerse(TM) 2Health News:Novalar Receives FDA Approval for OraVerse(TM) 3
...rchers have found that combining pre-operative che...e of survival by six percent when compared with su...rane Researchers from the MRC Clinical Trials Unit...tified 12 eligible randomised controlled trials. ...
...between potential benefits and potential harms whe...etes has to be assessed . This Cochrane Systemati...d a total of 8432 people and found no evidence tha...better patient outcomes when compared with other t...
...r after President Bush unveiled a plan for coping ...nt still has limited capacity to detect a disease...y. The government has also decided that it will no...u outbreak occurs somewhere in the world. Says Dr....
...he first six-month phase of a calorie-restriction ...tion Research Center on Aging (USDA HNRCA) at Tuf...and keeping them in check may be an important comp...ental results from the Comprehensive Assessment of...
Other Medicine News:Health News:Chemotherapy Better for Non Small Cell Lung cancer 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2Health News:Food Cravings are Linked to Weight Managenemt 2Health News:Food Cravings are Linked to Weight Managenemt 3
MIS Tibial Stylus
Ascent™ Anterior Referencing Femoral Instrument Case
The Lineage acetabular system with ceramic liners uses sophisticated manufacturing methods and materials to minimize wear debris generation.
Link All-Poly acetabular cups for cement.
Medicine Products: